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Available online 28 April 2016Background: GFAP is the major intermediate ﬁlament protein in mature astrocytes. Its increased expression and
aggregation was ﬁrstly associated to Alexander's disease, and successively in different neurological diseases
including scrapie, Alzheimer's and Creutzfeld–Jacob diseases. Recently, ceftriaxone a multi-potent β-lactam
antibiotic able to overcome the blood–brain barrier, successfully eliminated the cellular toxic effects of misfolded
mutated GFAP, similarly to phenytoin sodium, in a cellular model of Alexander's disease and inhibited
α-synuclein aggregation protecting PC12 cells from the exposure to 6-hydroxydopamine.
Methods: In this study, synchrotron radiation circular dichroism spectroscopy has been used to obtain structural
information about the GFAP-ceftriaxone (phenytoin) interactions, while computational methods allowed the
identiﬁcation of the relevant putative binding site of either ceftriaxone or phenytoin on the dimer structure of
GFAP, permitting to rationalize the spectroscopic experimental results.
Results:We found that GFAP exhibited enhanced stability upon the addition of two equivalents of each ligands
with ceftriaxone imparting a more spontaneous interactions and a more ordered complex system than phenytoin.
Conclusions: SRCD data andMDmodels indicate a stronger protective effect of ceftriaxone in neurological disorders
characterized by an increased production and polymerization of GFAP.
General signiﬁcance: This result, in addition to our previous works in which we documented that ceftriaxone
interacts with α-synuclein inhibiting its pathological aggregation and that a cyclical treatment with this
molecule in a patient with adult-onset Alexander's disease halted, and partly reversed, the progression of
neurodegeneration, suggests the possibility of a chaperone-like effect of ceftriaxone on protein involved
in speciﬁc neurodegenerative diseases.
© 2016Diamond Light Source Ltd. Published by Elsevier B.V. This is an open access article under the CCBY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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spectroscopy1. Introduction
Glial ﬁbrillary acidic protein (GFAP) is an intermediate ﬁlament (IF)
type III protein that, along with microtubules and microﬁlaments,
makes up the cytoskeleton of most eukaryotic cells. In addition to
vimentin, nestin and synemin, GFAP is a key component of the astrocyte's
cytoskeleton that warrants cell integrity and resilience [1]. To date 6
isoforms have been described from normal human and rodent sources,
and its molecular weight ranges from 48 kDa for mouse to 49 kDa for
human, 50 kDa for bovine, and 51 kDa for rat [2].emistry of CNR, Padua Unit, via
by Elsevier B.V. This is an open accessThe GFAP sequence can be split into three major domains: the
N-terminal head region, the central α-helical rod domain, and the
C-terminal tail region. The rod domain is highly conserved among
IF proteins. In GFAP, it is composed of 345 amino acid residues, containing
long tandem repeats of seven amino acid sequences called “heptad
repeats”. On the contrary, the size and amino acid sequences of the
head and tail regions vary among the different IF proteins. The head
domain of porcine GFAP, for example, is a highly basic region of 35-
amino-acid residues containing eight arginine residues, which adopts a
β-turn structure, while the tail region of approximately 50-amino-acid
residues has a globular structure [3,4]. Each of these regions plays a role
in the complex assembly process. The rod domain has a crucial role in
ﬁlament assembly, by facilitating coiling between IF proteins. The head
domain regulates the ﬁlament assembly and the end-to-end interactions,
while the tail domain that is involved in the stabilization of the
protoﬁlaments/protoﬁbrils by facilitating lateral interactions, modulatesarticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of protein in parallel and anti-parallel dimers through the interaction of
the rod domains of two polypeptides, that forming stable tetramers or
protoﬁlaments leads to the formation of protoﬁbrils [5].
GFAP, with microtubules and microﬁlaments, makes up the cyto-
skeleton of most eukaryotic cells and is the major IF in the adult brain
and in mature astrocytes [6]. These cells are involved in a wide range
of CNS pathologies, including trauma, ischemia and neurodegeneration
[7–10]. Indeed, in response to any CNS pathology, astrocytes undergo a
characteristic change in appearance with an increased production of IF
proteins [6]. Diseases that show increased GFAP protein include
Alzheimer's disease [9], scrapie [8] and Creutzfeld–Jacob disease [9].
The ﬁrst described neurologic disease associated with GFAP mutations
that results in a gain-of-function fashion is Alexander's disease [10].
This pathology is characterized by the presence of proteinaceous
aggregates in astrocytes, known as Rosenthal ﬁbers mainly composed
of GFAP, αβ-crystallin, and the heat shock protein HSP-27 [11]. Three
forms of AxD are recognized based on age of onset. The current view of
how GFAP mutations cause AxD is based on a combination of events
including the accumulation of GFAP and Rosenthal ﬁbers with the
sequestration of protein chaperones, and the activation of stress
response. Consequently, attention for therapeutics is now focused on
reducing the elevate level of GFAP as well as of Rosenthal ﬁber.
Interestingly, recent reports fromour group showed that ceftriaxone
(Cef, CAS number 104376-79-6, C18H16N8Na2O7S3·3.5H2O, Fig. 1), a safe
and multi-potent β-lactam antibiotic able to overcome the blood–brain
barrier [12], successfully eliminated the cellular toxic effects of
misfolded mutated GFAP in a cellular model of Alexander's disease
[13]. Moreover, clinical ﬁndings indicated that the chronic, cyclical
intravenous administration of ceftriaxone in a patient with adult-onset
Alexander's disease induced a positive clinical outcome [14], and a four-
year-long extension of the trial with ceftriaxone in this patient showed
that the progression of neurodegeneration was halted and/or reversed
by ceftriaxone, with a signiﬁcant improvement of the quality of life of
the patient [15].
The neuroprotective activity of Cef has been also documented in
many experimental models of cerebral ischemia, amyotrophic lateral
sclerosis, Parkinson's disease, and epilepsy [16,17]. Purported mecha-
nisms involved include the ability ofCef to increase the glutamate trans-
porter subtype 1 (GLT-1) activity in astrocytes that are impaired in their
GLT-1 expression, and the enhancement by this drug of the degradation
of misfolded proteins through a still undetermined mechanism [15].
Notably, the possibility of a direct interaction of this molecule with
GFAP as a mechanism to exert its effect has not been investigated
remaining elusive. Recently, we demonstrated that Cef is able to
interact with α-synuclein inhibiting the protein aggregation and to
protect PC12 cells from the exposure to oxidopamine, also known
as 6-hydroxydopamine (6-OHDA) [16]. Thus, the characterization
of the interaction between ceftriaxone and GFAP is crucial for brain
research, in order to elucidate at molecular level the inhibitory effect
of ceftriaxone to GFAP protein involved in neurodegenerative diseases. In
this study, we investigate the ability of ceftriaxone to interact with GFAP
using both physicochemical techniques and computational methods.
The same approaches were used to study the interaction of GFAP with
phenytoin sodium (PHT, CAS number 630-93-3, C15H11N2NaO2), anFig. 1. Chemical structures of ceftriaxone sodium saold anticonvulsant drug used in the treatment of epilepsy [18], with
well-known neuroprotective properties [19], which is also able to
counteract and protect cells from the toxic effects of mutated GFAP
in a cellular model of Alexander's disease (unpublished data). Synchro-
tron radiation circular dichroism (SRCD) spectroscopy has been used to
obtain structural information about the GFAP-ligands interactions and
the effect of Cef and PHT molecules on the protein photo and thermal
stability. The high sensitivity of SRCD spectroscopy to sample perturba-
tions enables the investigation of ligand-binding interaction that could
not be attempted by any other technique in terms of speed, ease, and
small amount of material required [20].
Computational methods allowed the identiﬁcation of the relevant
putative binding site of either Cef or PHT on the dimer structure of
GFAP, permitting to rationalize the spectroscopic experimental results.
We have found that both Cef and PHT interacted with GFAP increas-
ing the content of ordered structure as well as enhancing its photo and
thermal stability. These results suggests that a direct action of Cef and
PHT on GFAP stability might play a role in the therapeutic action of
this molecule in halting and/or reversing the neurodegenerative pro-
cesses associated with Alexander’ disease. Moreover, these ﬁndings
suggest that PHTmight have a therapeutic role similar to ceftriaxone
in Alexander's disease.
2. Materials and methods
2.1. Synchrotron radiation circular dichroism spectroscopy
Lyophilised w.t. GFAP from human brain was purchased from
GenWay Biotech (Fig. S1 in Supporting Material). Ceftriaxone and
phenytoin sodium were obtained from Sigma-Aldrich. GFAP was
reconstituted with deionized water obtaining a carbonate buffer
solution at concentration of 0.66 mg/ml. Ligand solutions (270 μM)
were prepared in deionized water. Sample concentrations were deter-
mined by UV–Vis spectroscopy. SRCD spectra from 180 to 260 nm were
collected at Diamond B23 beamline module end-station B using
bandwidth = 1.1 nm, integration time of 1 s, 1 nm digital resolution,
39 nm/min scan speed. Spectra were measured using Suprasil cell
(Hellma Ltd.) with 0.02 cm pathlength. Thermal stability was monitored
in the 5–90 °C temperature range at 5 °C incrementswith 5min equilibra-
tion time using Quantum Peltier temperature controller. Protein UV
photo-denaturation was investigated measuring twenty consecutive
repeated scans for each sample. SRCD spectra were processed and ana-
lyzed using CDApps software [21].
2.2. Docking and molecular dynamics simulations
The homology modeling procedure for GFAP Rod Domain was
described in the SupportingMaterial. Starting ceftriaxone and diphenyl-
hydantoin ligand geometries were built with Ghemical 2.99.2 [22], and
energy minimized at molecular mechanics level ﬁrst, using Tripos 5.2
force ﬁeld parametrization [23], and then at AM1 semi-empirical level.
The AM1-EM ligand structures were fully optimized using GAMESS
program [24] at the Hartree-Fock level with STO-3G basis set, followed
by a single-point HF energy evaluation at the 6-31G* level to derive the
partial atomic charges for the ligands by the RESP procedure [25].lt (Cef) (1) and phenytoin sodium (PHT) (2).
Fig. 2. Far-UV SRCD spectra of GFAP in aqueous solution in presence or absence of
ceftriaxone (A) or phenytoin (B).
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AutoDockVina 1.1.2 [27]. The representative frames from MD simula-
tions of each modeled GFAP region (see supporting material) and both
ligands were processed with AutoDock Tools (ADT) package version
1.5.6rc1 [26] to merge non-polar hydrogens and calculate Gasteiger
charges. Since potential ligand binding sites were unknown in advance,
the whole modeled sequence of GFAP had to be targeted in docking.
While the CC axes of the different GFAP fragments exhibit in general a
locally variable curvature, both docking programs can only explore
rectilinear boxes. Thus, to ensure a uniform sampling around the axis
of each CC segment, sampling was performed on partially overlapping
grids along the protein fragments, centered on “local sub-axis”, (gener-
atedwith the programAutoGrid 4.2 of Autodock 4.2 using 0.375 Å spac-
ing and 100× 100× 100 points), rather than a single grid encompassing
the whole length of each CC segment and centered on the average
segment axis. Hundred molecular AutoDock docking runs for each
docking calculation were performed adopting a Lamarckian Genetic
Algorithm (LGA) and the following associated parameters: 100 individ-
uals in a population with a maximum of 15 million energy evaluations
and a maximum of 37,000 generations were followed by 300 iterations
of Solis andWets local search. Flexibilitywasused for all rotatable bonds
in both docked ligands. For each docking run from both Autodock and
AutoDockVina, the poses with lowest predicted Autodock binding free
energy within each highly-populated binding mode were selected for
the subsequent molecular dynamics (MD) simulations of ligand-GFAP
complexes.
For each ligand-protein complexes the addition of all hydrogen
atoms, EM and MD simulations with Amber12 pmemd.cuda module
[28,29] were carried out using ff12SB version of AMBER force ﬁeld
[30] for the protein and gaff parameters [31] for the ligands. MD simu-
lation protocol was described in the supporting material.
2.3. Visual inspection, graphical analysis and structural Figs.
Visual inspection and graphical analysis were performed with VMD
1.9.2 [32] (also used to draw panels of Fig.M2) andUCSF Chimera 1.10.1
[33] (also used for panels of Figs. 7–10).
3. Results
3.1. Effects of Cef or PHT on the secondary structure of GFAP
The far-UV SRCD spectrum of GFAP in aqueous solution at 20 °C is
characterized by the presence of a strong positive band at about
190 nm, and two negative bands at about 208 and 219 nm, diagnostic
of the presence of an α-helical conformation component (Fig. 2). The
addition of two equivalents of both ceftriaxone (Cef) and phenytoin
(PHT), respectively, affected the far-UV SRCD spectrum of GFAP by
increasing its CD intensity (Fig. 2 and Table 1). This unambiguously
indicated that the both ligands bind to GFAP increasing its content of
α-helical conformation by 14% and 16% respectively (Table 1).
3.2. Effects of Cef and PHT on both photo-induced and thermal GFAP
denaturation
The protein stability of GFAP with and without ceftriaxone or
phenytoin ligand was assessed with both UV photo and thermal
denaturation assays.
The highUVphoton ﬂux of B23 beamline can denature proteins [35].
Indeed, a signiﬁcant decrease of secondary structure upon light irradia-
tionusing intense far-UV radiations iswell observable in structured pro-
teinswith signiﬁcant content ofα-helical and/or β-sheet conformations
[36]. Like thermal denaturation, UV denaturation varies from protein to
protein, and in the presence of ligands [20]. Protein denaturation in-
duced by far UV radiation has been attributed to the formation of free
radicals [37]. Previous studies using B23 beamline [28,38-42] hasruled out thermal stress from local heating induced by high photon
ﬂux in the farUV region. Thiswas conﬁrmed bydifferent rates of confor-
mation loss (denaturation) of the protein under heating and UV irradi-
ation. The mechanism of photo-denaturation is likely to include free
radical damage to the photosensitive residues tryptophan and tyrosine,
as well as the oxidation of amino acid residue side chains [37,39–41].
Tyrosines are present in GFAP, which may explain the irreversible loss
of conformation during UV irradiation. However, this phenomenon
can be exploited as a protein UV-denaturation assay to assess the effect
of the environment (solvent composition, detergents, pH, and ligands)
on protein photo stability and speciﬁcally for ligand-protein binding in-
teractions [20,36,39,42–46].
The UV-denaturation assay was carried out by measuring twenty
consecutive repeated scans in the180–250nmfar-UV regionof aqueous
GFAPwith andwithout ceftriaxone (Cef) and phenytoin (PHT) (Fig. 3A,
B and C). By keeping constant all the instrument parameters such as
protein concentration, cell pathlength, volume of solution used to ﬁll
the cuvette cell, photon ﬂux of the irradiating incident light that for
the synchrotron beamline is characterized by the ring current value,
the SRCD spectral changes were indicative of protein denaturation.
This was better illustrated by the plot of SRCD intensity at single wave-
length versus the number of scans. The ﬁtting of the experimental data
using 1st or 2nd order exponential equations (CDApps) can be seen as
Table 1
a-Helix content and thermodynamic properties of GFAP in presence or absence of ceftriaxone (Cef) or phenytoin (PHT) calculated using CONTINLL [34] of CDApps [21].
Δε % α-Helix Tm (K) ΔH (JM−1) ΔS (JK−1 M−1)
190 nm 208 nm 219 nm
GFAP 2.65 −1.95 −1.68 37 324.8 (51.8 °C) 91804 274.3
bGFAP + Cef 3.42 −2.31 −2.09 42 (N14%a) 331.2 (58.2 °C) 68451 205
bGFAP + PHT 3.45 −2.37 −2.06 43 (N16%a) 328.3 (55.3 °C) 148147 443
a The percentage is calculated from the ratio of α-helical percentage of the complex over that of GFAP.
b The value of α-helical content for the calculated GFAP + Cef and GFAP + PHT is similar to that of GFAP alone (37% α-helix).
2242 P. Ruzza et al. / Biochimica et Biophysica Acta 1860 (2016) 2239–2248the relative rates of UV-denaturation between GFAP with and without
ceftriaxone and phenytoin ligands (Fig. 4A). Ceftriaxone appeared to in-
crease the GFAP photo-stability much more than that induced by phe-
nytoin. The rates of UV-denaturation of the GFAP complexes with Cef
and PHT being different than that of GFAP were unambiguously
indicative of ligand binding interactions. This was also consistent with
the estimated amount ofα-helical content from each of the 20 repeated
consecutive SRCD scans that were different for GFAP + Cef and
GFAP + PHT compared to that of GFAP (Fig. 4B). The one for
GFAP + PHT appeared to be into two steps. However, the fact that the
rates of UV-denaturation of the GFAP complexes were signiﬁcantly
different among themselves is an important observation, as this was
not the case for the thermal denaturation studieswhere both complexes
showed similar melting curves (Fig. 5B).
To conﬁrm that the observed changes in the far-UV SRCD spectra of
GFAP or complexed with the Cef and PHT ligands were not due to
photo-induced protein fragmentation, electrophoresis of the irradiated
samples were conducted showing that no new bands, in addition to
those present in the starting material, were detected on the gel
(Fig. S1) conﬁrming the integrity of the protein in the ﬁrst and last
SRCD scans of the UV-denaturation assay experiments.
The temperature study of GFAP in the 5–90 °C temperature range
revealed a partially reversible protein denaturation (Fig. 5A). On the
contrary, in the presence of the two equivalents of ceftriaxone and
phenytoin ligands the thermal denaturation of GFAP-ligands mixtures
was more reversible than GFAP without ligands (data not shown).
Both Cef and PHT ligands enhanced the thermal stability of GFAP
(Fig. 5B) by increasing melting temperature Tm from 51.8 °C to 58.2 °C
and 55.3 °C respectively (Table 1). Enthalpy of the complex with Cef
(~68 kJM−1) is much smaller than that of the complex with PHT
(148 kJM−1) suggesting that the complex with PHT is less favorable
than the complex with Cef. This is also seen in the entropy of the
complex with Cef (205 JK−1 M−1) which is smaller than the complex
with PHT (443 JK−1 M−1), showing that the complexwith PHT induces
more disorder behavior of the complex while the presence of Cef
induces more ordered structure to the complex compared to the GFAP
alone (~92 kJM−1) with entropy larger than the complex with Cef.3.3. Homology modeling of GFAP predicted coiled-coil regions
GFAP (73–377), known as “rod” domain, exhibits the following
predicted topologically organization (numberings in parenthesis corre-
spond to the hGFAP sequence from UNIPROT: P14136): Coil 1A (73–
104), Linker 1 (105–115), Coil 1B (116–214), Linker 1–2 (215–230),
Coil 2A (231–252), Linker 2(253–256), Coil 2B (257–377). PSI-BLAST
Similarity searches in the PDB dataset allowed the modeling of four
dimeric CC region fragments, i.e. Coil 1A (73–104), Coil 1B (112–215),
Coil 2A–2B (231–301) and Coil 2B (279–373), by using as templates
the X-ray structures of Vimentin (PDB: 3G1E for Coil 1A, PDB: 3UF1
for 1B and PDB: 3TRT for 2A–2B) and Keratin (PDB: 3TNU for Coil 2B).
Modeled regions share sequence identities of more than 60% with
Vimentin template structures (Coil 1A: 75%, Coil 1B: 61%, Coil 2A–2B:
64%) and 42% with Keratin (Coil 2B).Consistently with Vimentin structure, GFAP Coil 2A and 2B were
modeled as a single continuous α-helical CC. GFAP Coil 2A–2B and
Coil 2B have a short (22 aa) overlapping sequence. However, since we
focused on possible binding modes of ceftriaxone and phenytoin to
GFAP rather than on the structure of GFAP itself, we did not merged
the two fragments, to facilitate the subsequent docking step.
The representative MD structures of each modeled GFAP CC region
to be used in the subsequent docking calculations were obtained by a
combined iterative ﬁt and cluster analysis, described in “Methods” in
the SupportingMaterial. Topological organization and CCmotifs identi-
ﬁed by SOCKET v. 3.02 [47] on the different representative modeled
structures are illustrated in Fig. 6.3.4. Molecular docking of Cef and PHT on GFAP
Docking calculations on Cef and PHT were performed with both
Autodock [26] and AutoDockVina [27] programs, by a “multiple
overlapping window” strategy, fully described in the “Methods”
section, speciﬁcally devised for blind (i.e. on unknown binding site)
docking on CC target structures. Brieﬂy, docking was run for each
compound in one to ﬁve (depending on the length of the modeled
CC) consecutive and partially overlapping grid boxes for each GFAP
fragment, to ensure a uniform distribution of sampled regions around
the coil axes along all modeled fragments of GFAP, independently on
the local CC curvature.
Both ligands exhibit an irregular distribution of the predicted binding
poses for all CC segments, with 45 and 48 highly-populated “macrosites”
for Cef and PHT, respectively (three for Cef and ﬁve for PHT in CC 1A,
fourteen for Cef and eleven for PHT in 1B, ten for Cef and ten for PHT in
2A–2B, eighteen for Cef and twenty-two for PHT in 2B), corresponding
to disjointed, multiply-populated blobs in Fig. 7.3.5. MD reﬁnement of selected complexes
Theposes exhibitingmost favorable predicted binding free energy in
each highly-populated binding site were selected for MD simulation to
assess the dynamic stability of the complexes.
The ligand-protein interaction energy, reported in Table S1 in the
Supporting Material, along with the drift from the starting position
and the time interval of stability, was calculated for poses that either
were stable during a whole MD run, or rearranged to a new pose,
stable for at least 6 ns of MD. For each ligand, only the structures
within an energy cutoff of 40 kcal mol−1 from the absoluteminimum
of all complexes (bold energy values in Table S1) are discussed in
detail in the subsequent sections. Hereafter “A” and “B” superscripts
label residues from themodel chains alignedwith chains A or B of the
corresponding PDB templates, respectively, while standard H-bonds,
and H-bonds reinforced by ionic interactions are abbreviated as HB
and HB-II, respectively. The protein residues involved in the main
interactions with ligands for each selected complex model, discussed
in the following section, are also reported in Table S2 in the Supporting
Material.
Fig. 3. GFAP UV-denaturation assay. A) Twenty repeated consecutive CD scans of GFAP
(0.66 mg/ml) in aqueous solution measured with B23 module B. The solid black line
indicates the ﬁrst scan and the solid red line the 20th scan. Integration time 1 s, 0.02 cm
cylindrical cell (30 μl), monochromator slit widths 0.500 mm (1.2 nm band width (bw)).
B) Twenty repeated consecutive CD scans of GFAP-ceftriaxone (Cef) (1:2) complex in
aqueous solution measured with B23 module B under the same experimental conditions.
C) Twenty repeated consecutive CD scans of GFAP-phenytoin (PHT) (1:2) complex in
aqueous solution measured with B23 module B under the same experimental conditions.
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Five and three poses for Cef and PHT, named Cef/1A/1–5 and PHT/
1A/1–3 (see Supporting Material for pose naming scheme), respectively,
were selected from docking step and reﬁned by MD runs of 10–25 ns
(length depends on ligand rearrangement during MD). Stable poses for
both ligands are highlighted in Table S1. In Cef/1A/4/md (Fig. 8B), Cef
ﬁts along the cleft between the two CC helices, forming with helix A a
parallel-displaced π-stacking between its dioxotriazine ring and Phe89A
sidechain, HB-II with Lys86A and HB between its amino group and
Glu100A, and with helix B a HB-II between the carboxylate group and
Lys95B. No PHT/1A complex exhibits an average interaction energy
within the cutoff energy value, thus they will not be discussed in detail.
3.7. Complexes of Cef and PHT with Coil 1B
Due to the length of CC 1B, docking calculations were performed on
ﬁve overlapping windows, i.e. w1 to w5, respectively providing ﬁve
(Cef/1B/1–5), six (Cef/1B/6–11), four (Cef/1B/12–15), six (Cef/1B/16–
21) and six (Cef/1B/22–26) poses for Cef, and four (PHT/1B/1–4), two
(PHT/1B/5–6), two (PHT/1B/7–8), four (PHT/1B/9–12) and two (PHT/
1B/13–14) poses for PHT, which were subsequently reﬁned and
assessed by MD runs of 10–30 ns, depending on the degree of pose
rearrangement.
Among Cef complexes falling within the energy cutoff (Cef/1B/6, 9,
14, 19, 22) only in Cef/1B/22/md the ligand interacts with a single CC
helix, whereas in the other poses it grafts the two CC helices together.
Ligand, in stable complexes, is located both toward the N-terminus
(Cef/1B/6, 9/md), and in the middle (Cef/1B/14/d), and toward the C-
terminus of the CC (Cef/1B/19, 22/md). Although in Cef/1B/6/md
(Fig. 9C) Cef is mainly wrapped around helix A, it also forms strong
HB-II interactions with Arg126B on helix B, with both its dioxotriazine
ring, and the carboxylate moiety. This latter, in turn, is also involved in
HB-II with Arg124A, thus bridging the two helices, turning a potential
repulsive Arg-Arg inter-helical contact into a strong favorable Arg-
carboxylate-Arg three-molecular interaction. The aminoimidazole
group forms ionic-π interactions with Arg121A. A similar binding
mode occurs in Cef/1B/9/md (Fig. 9D) where the dioxotriazine ring
ﬁts between the two helices, forming HB-II with both Arg126A and
Arg124B, while the aminothiazole ring engages a cation-π interaction
with Arg136A. In Cef/1B/14/d (Fig. 9E), Cef lies in the inter-helical
cleft, forming a network of HB-II involving the aminothiazole ring and
both Asp147A and Arg162B, dioxotriazine ring and Arg152B, whereas
the carboxylate group forms HB-II with Lys154A. In Cef/1B/19/md
(Fig. 9F), Cef is perpendicular to the CC axis and its dioxotriazine ring
and carboxylate group engage cation-π and HB-II interactions, respec-
tively, with Arg188A. In addition, Cef amide carbonyl is H-bonded to
Lys189A and the aminothyazole group points toward Glu187B, forming
a low-persistence HBs during MD. In Cef/1B/22/md (Fig. 9G), Cef inter-
acts mainly with a cluster of positively charged residues, i.e. Arg198A,
Arg201A and Lys202A, with both the dioxotriazine ring and the carbox-
ylate moiety. It also forms hydrophobic interactions between its
methoxymethyl group and Leu193B/Glu196B.
Among PHT/1B complexes, only PHT/1B/6/md (Fig. 9B) exhibited
an average interaction energy within the cutoff. Here, PHT lies
toward the N-terminus of CC and interacts with both helices, being
its dioxoimidazolidine ring involved in a network of HBs and HB-II
with Gln117B, Arg121B and Arg124B on one helix and with Tyr116A,
on the other. This latter residue also forms π-stacking interactions
with one PHT phenyl ring.
3.8. Complexes of Cef and PHT with Coil 2A-2B
Docking calculations of CC 2A–2B were performed on three overlap-
ping windows, i.e. w1 to w3, respectively providing ﬁve (Cef/2A–2B/1–
5), three (Cef/2A–2B/6–8) and six (Cef/2A–2B/9–14) poses for Cef, and
Fig. 4. SRCD intensity and secondary structure content versus the number of scans. A) Plot
of the SRCD signal at 191 nm for GFAP (black), GFAP+ Cef (1:2) (Red); and GFAP+ PHT
(1:2) (blue) versus number of scans. B) Plot of α-helix content for the GFAP (black),
GFAP + Cef (1:2) (Red); and GFAP + PHT (1:2) (blue) determined with CONTINLL [34]
of CDApps [21] from SRCD data versus number of scans. For all measurements GFAP
concentration was 0.66 mg/ml, ligand concentration was 12 μM, protein/ligand ratio
was 1:2. Ligands are ceftriaxone (Cef) and phenytoin sodium (PHT). The SRCD spectra
(unsmoothed) were measured using B23 module B, integration time 1 s, 0.500 mm
slit-width that corresponds to 1.2 nm bandwith using a cylindrical Suprasil cell of 0.02 cm
pathlength (Hellma) ﬁlled with 30 μl of solution. The green lines are the shifted black line
to illustrate the different slope of the red and blue lines.
Fig. 5. GFAP thermal denaturation assay. A) Far-UV SRCD spectra of GFAP in aqueous
solution measured with B23 module B at different temperatures. GFAP was 0.66 mg/ml;
integration time 1 s, 0.02 cm cylindrical cell (30 μl), monochomator slit widths 0.280 mm
(0.5 nm bandwidth) to eliminate the effect of UV denaturation. B) Plot of the fraction of
denaturated protein calculated from the ellipticity values at 190 nm versus temperature.
GFAP (black), GFAP + Cef (1:2) (Red); and GFAP + PHT (1:2) (blue).
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6–12) poses for PHT, selected for MD reﬁnement and assessment.
Among Cef poses that gave stable complexes only Cef/2A-2B/12, 13/
md fell within the cutoff energy range. In both complexes, Cef is located
at about 2/3 of the CC sequence. In Cef/2A–2B/12 (Fig. 10B), Cef is
wrapped along helix B, engaging with its aminoimidazole ring both π-
stacking and cation-π interactionwithHis281B and Arg277B, respectively.
It also forms a bidentate HB-II between its carboxylate moiety and
Lys280B/Arg287B. This latter residue also engages ionic interactions with
dioxotriazine ring, which, in turn, forms HBs with Gln291B. In Cef/2A–
2B/13/md (Fig. 10C), instead, Cefmolecule lies in the CC cleft, interacting
with both helices by a network of HB-II and HBs involving its
dioxotriazine ring and Arg271A/Asn272A, its carboxylate and carbonyl
moieties and Lys280B and its aminothiazole ring and Asn284B,
aminothiazole ring also engaging a cation-π interactions with Arg287B.
Among PHT complexes, only PHT/2A–2B/9/md (Fig. 10D) showed
average energy-interaction very close to the cutoff. PHT is locatedtoward the C-terminal end of CC and mainly interacts with helix A:
the dioxoimidazolidine moiety forms a network of HBs with Ser292A,
Gln289A and HB-II with Arg288A, whereas a phenyl group engages
hydrophobic interactions with both Leu293A and Leu290B.
3.9. Complexes of Cef and PHT with Coil 2B
Docking calculations on CC 2B were run on ﬁve overlapping win-
dows, i.e. w1 to w5, respectively providing the following selected
poses for the MD assessment: three (Cef/2B/1–3), three (Cef/2B/4–6),
seven (Cef/2B/7–13), six (Cef/2B/14–20) and eight (Cef/2B/21–27)
poses for Cef, and four (PHT/2B/1–4), three (PHT/2B/5–7), eight
(PHT/2B/8–15), four (PHT/2B/16–19) and ﬁve (PHT/2B/20–23) poses
for PHT. Among the stable Cef poses, only Cef/2B/2/md (Fig. 10H)
exhibited an average energy value within the cutoff. The ligand is located
toward the N-terminus of the protein, perpendicularly to the CC axis and
spanning both the helices: the dioxotriazine ring and the carboxylate
group engage HBs with Gln291B and HB-II with Arg287B, respectively,
whereas the aminoimidazole ring and the carbonyl group of amidic
moiety form HBs with Asp296A and Gln291A, respectively. Among PHT
complexes, two of them, i.e. PHT/2B/2/md (Fig. 10F) and PHT/2B/3/md
(Fig. 10G) fell within the energy cutoff, sharing a very similar binding
Fig. 6. Annotated sequence of hGFAP rod domain. hGFAP(73–377) from UNIPROT: P14136 is shownwith: predicted topological elements listed on the left and, for coils 1A, 1B, 2A and 2B,
also highlighted with light green, magenta, cyan, blue background, respectively; modeled regions enclosed in shadowed boxes; CC motifs identiﬁed by SOCKET v. 3.02 [46] in the
representative models in bold (1A = 19aa; 1B = 86aa; 2A–2B = 35aa; 2B = 78aa, with the corresponding heptad (abcdefg) assignment one row below); model 2A–2B/2B
overlapping region boxed in red. SOCKET assignments for both 2A–2B and 2B segments (consistently labeled in parentheses) are shown under the ﬁrst row of the coil 2B sequence.
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mainly interacting with only one helix of CC. Its dioxoimidazoline ring
forms a network of HB-II and HBs with Arg287A, Arg288A (both poses)
and Gln291A (only PHT/2B/2/md), while one phenyl ring engages hydro-
phobic interactions with Leu290A and, in PHT/2B/2/md only, the other
forms a π-stacking with Tyr285B, the only relevant interaction with the
second CC chain.
3.10. Inﬂuence of complexation on protein local structural stability
To evaluate the effects of the different complexes on the structural
stability of protein segments, an analysis (Table S2) of protein backbone
atom rmsd focused on “local” (i.e. around the binding site of each
ligand) interactions, as described in detail in “Methods”, was performed
on the ﬁnal set of structures highlighted in Table S1. This “local”
approach gets rid of possible noise fromboth long timescale “breathing”
motions of the segments (under sampled on the simulated timescales)Fig. 7.Distribution ofCef and PHTdocking poses for differentGFAP segments. Transparent
surfaces (violet: Cef, light gray: PHT) enclose docked ligand centers of selected poses in all
the complexes with GFAP (1A), (1B), (2A–2B) and (2B). GFAP segments are represented
by ribbons colored by an “absolute-scale, per-protein rainbow” scheme, ranging from
red (N-terminus of the A chain) to cyan (C-terminus of the B chain of the longest, i.e. 1B,
sequence), and accordingly narrower scales for shorter segments.and instant tomedium timescale randomﬂuctuations, especially affecting
the terminal regions of the segments and potentially ampliﬁed by their
elongated shape.Fig. 8. Structure of the 1A modeled protein segment and of the corresponding selected
complexes with Cef or PHT. The representative structure of the 1A (A) GFAP segment is
shown in ribbon representation, with a “relative-scale, per-chain rainbow” coloring
scheme, ranging from red (N-terminus) to blue (C-terminus) for each chain of each
sequence. Panel (B) shows the binding regions of the selected 1A complex: Cef/1A/4/
md. Protein ribbons and sidechain carbon atoms are colored as in (A). Cef is shown in
ball-and-stick representation, with carbon atoms colored in magenta. Protein sidechains
within 5 Å from ligands are shown as sticks. Protein-ligand H-bonds are represented as
green “springs”. Nitrogen, oxygen, sulfur, hydrogen atoms are colored blue, red, yellow
and white, respectively.
Fig. 9. Structure of the 1B modeled protein segment and of the corresponding selected complexes with Cef or PHT. The representative structure of the 1B GFAP segment (A) and the
binding regions of selected 1B complexes: PHT/1B/6/md (B), Cef/1B/6/md (C) Cef/1B/9/md (D), Cef/1B/14/d (E), Cef/1B/19/md (F) and Cef/1B/22/md (G), are shown using the same
representations and coloring schemes described in Fig. 8.
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In previous work, we documented that a chronic, cyclical treatment
with Cef in a patient with adult-onset Alexander's disease halted, and
partly reversed, the progression of neurodegeneration [14,15]. Recently,
we found that ceftriaxone interacts with α-synuclein and inhibits its
pathological aggregation [16], suggesting the possibility of a
chaperone-like effect of this molecule on protein involved in speciﬁc
neurodegenerative diseases [48]. These ﬁndings prompted us to evaluate
the occurrence of a direct effect of ceftriaxone on GFAP.
We have demonstrated that GFAP stability was increased by the
binding interactions with Cef (Figs. 4 and 5B). SRCD spectra showedFig. 10. Structure of the 2A-2B and 2Bmodeled protein segments and of the corresponding selec
and the binding regions of selected 2A–2B (B–D) and 2B (F–H) complexes: Cef/2A–2B/12/md (
Cef/2B/2/md (H), are shown using the same representations and coloring schemes described ithat the addition of Cef increased the content of α-helical structure on
native hGFAP, increased the protein melting temperature TM and
reduced the UV photo denaturation (Figs. 4 and 5B). Similarly, PHT, an
antiepileptic drug with deﬁnite neuroprotective activity [19], which is
also able to counteract the toxic effects of mutated GFAP in a cellular
model of Alexander's disease (unpublished data), interacted directly
with GFAP increasing even more the content of α-helical conformation
than that with Cef (Table 1). On the other hand, PHT resulted to be less
efﬁcient to protect GFAP toward UV and thermal denaturation (Figs. 4
and 5B).
In order to understand how Cef and PHT interact with GFAP, we
conducted computational studies to predict the potential binding sitested complexeswith Cef or PHT. The representative structures of the 2A–2B (A) and 2B (E)
B), Cef/2A–2B/13/md (C), PHT/2A–2B/9/md (D), PHT/2B/2/md (F), PHT/2B/3/md (G) and
n Fig. 8.
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provided structures exhibiting a considerable conformational stability
on the 101 ns timescale simulated for their MD reﬁnement.
Modeling of GFAP complexes with Cef and PHT shows that both
ligands can formnon-covalent complexes stable on a N101 ns timescale.
However, the lack of a canonical “binding site”, intended as a more or
less deep concavity, like those observed in most receptor or enzyme
active sites, implies that both the nature of the binding, and its strength
cannot be evaluated with the usual standards and protocols of more
canonical complex examples. In particular, MD identiﬁed four main
classes of dynamic behaviors of the ligands: 1) “labile”, in which the
interaction predicted by docking is lost during the MD and the ligand
moves away from the protein, 2) “traveling”, where ligand loses its
starting protein interactions during theMD, but it moves on the protein
surface, always preserving some direct contact with it; 3) “rearranging”,
inwhich the ligandmoves away from its starting position, but it reaches
within few ns a new pose, stable for at least 6 ns, until the end of the
simulations; 4) “stable”, where the ligand remains in the starting pose
during the whole MD simulation. In particular, the occurrence of “travel-
ing” and “rearranging” complexes, in addition to the aforementioned lack
of deep binding sites, is also favored by the high occurrence of similar,
repeating patterns of hydrophobic and charged (especially basic) residues
along a considerable fraction of the modeled CC sequences.
The only partial exception to the lack of a binding cavity is represented
by the (quite shallow, indeed) clefts between CChelices and parallel to CC
axis: in this view it is not surprising that the only observed low-energy
“stable” pose, Cef/1B/14/d, exhibits the ligand in an inter-helical cleft,
lying parallel to the CC axis.
Since the nature of the complexes and their high dynamic ranges
make the quantitative evaluation of ligand afﬁnities an even more
than usually elusive task, we will only discuss emerging qualitative
and macroscopic quantitative features of the different complexes and
ligands.
The comparison between the two ligands shows that Cef provides a
larger number of low energy and persistent poses than PHT (nine vs.
four with our computational approach and a 40 kcal mol−1 cutoff on
the protein-ligand interaction energy). This behavior is consistent
with SRCD results showing that PHT is less efﬁcient in protecting
GFAP against UV- and thermal denaturation. The ligand distribution
along the protein segments exhibits low energy poses in all modeled
sequences for Cef, with a peak in the 1B CC, where ﬁve out of the nine
low energy and persistent poses are found. However, when the
standard topological organization is considered, we must observe that
no selected complex involves the 2A CC region, since all the selected
poses in 2A–2B model dock toward the C-terminus, i.e. in the 2B part,
in a sequence that overlaps the 2B segment N-terminus, exhibiting a
very similar binding mode to the best complexes selected for this latter
region. In the case of PHT, ligand is observed in low energy and persis-
tent poses only in 1B (one pose) and in the overlapping 2B region corre-
sponding to the C-terminus of 2A–2B and the N-terminus of 2B
sequences (three poses).
When considering the possible implication of the predicted ligand
binding on overall tertiary and quaternary structure of GFAP, although
we cannot exclude effects deriving from eventual interactions of the
ligands with regions of GFAP that could not be modeled, some possible
effects of binding on protein structure can be predicted from our
models.
In principle, the binding of a ligand on a CC can affect the stability
of the coil and of the single intervening helices either negatively, by
disrupting or altering a pattern of sidechain–sidechain, or even
sidechain–backbone/backbone–backbone interactions, strongly contrib-
uting to the stability of both structures, or positively, by aspeciﬁc patching
of apolar patches on the protein surface, or by speciﬁc protein-ligand
stabilizing interactions.
A comparison of the local rmsd ﬂuctuations of the protein backbone
atoms between free and complexed protein MD simulations (Table S2),shows that the stability of helices and CCs, although already very good
in the MD models of unligated segments (see “Homology Modeling of
GFAP predicted coiled-coil regions”), is generally improved upon binding
of Cef, and, to a lesser extent, PHT. In particular, is considerable (N15%) in
seven of the selected poses (six for Cef and one for PHT), signiﬁcant
(about 8%) in two poses (one for Cef and one for PHT), and marginal
(b5%) in the other four selected poses (two for Cef and two for PHT). In
this view, an overall net stabilization of the helical structure upon binding
is expected for the two ligands, especially in ligand concentration ranges
where multiple-binding states are signiﬁcantly populated. This stabiliza-
tion is fully consistent with the increase in helicity suggested by SRCD
results in the presence of Cef and PHT (Table 1).
However,when comparing their bindingmodes, a different behavior
between the two ligands is observed. Cef appears to bind preferentially
to canonical CC conformations that are all located in regions identiﬁed
by SOCKET v. 3.02 belonging to CC motifs, except for three residues
out of 36 listed in the table (Arg201A and Lys202A for Cef/1B/22/md
and Arg287B for Cef/2B/2/md) that are within two residues of the
ends of the corresponding CC motifs. PHT, on the other hand, appears
to prefer the less-regular regions at both ends of canonical CC motifs
as three out of 17 listed residues lies outside the canonical + two-adja-
cent-residue region. Only one out of the four selected models (PHT/
2 A-2B/9/md) interacts with residues within canonical CC motifs. This
behavior can be attributed to the relatively small size of PHT, which is
unable to full “clamp” either a single helix or, even more, a CC helix
pair, and thus can form stable complexes by lying in the cleft between
two interacting helices. However, since the cleft formed by canonical
CCmotifs is quite narrow and very shallow, it represents a good binding
site only when its considerable length can be fully exploited by a
properly-sized and shaped ligand, like for Cef in the following com-
plexes: Cef/1A/4/md (Fig. 8B), Cef/1B/14/d (Fig. 9E) and Cef/2A–2B/
13/md (Fig. 10C). In this view, the wider inter-helical clefts located in
regions immediately surrounding the canonical CC motifs provide a
better binding site for a ligand of the size and shape of PHT. Overall,
Cef and PHT appear to stabilize prevalently CC structures by different
mechanisms; Cef by stabilizing the CC motif itself by clamping the two
helices together and/or enforcing their interactions and covering their
surfaces along the inter-helical cleft; PHT by locking potentially ﬂexible
hinge regions ﬂanking canonical CC motifs.5. Conclusions
This study determined the binding of Cef andPHTdrugs to hGFAP by
SRCD spectroscopy and examined how these ligands might interact
with predicted coil-coiled regions of the hGFAP protein by molecular
docking and dynamics. We observed that both these molecules interact
directly with GFAP increasing the content ofα-helical structure. UV and
thermal denaturation assays revealed that GFAP exhibited enhanced
stability upon the addition of two equivalents of each ligands with Cef
imparting amore spontaneous interactions than PHT andmore ordered
complex system than PHT. GFAP-ligand complexes in particular with
higher ligand stoichiometry either by high ligand concentration and/
or afﬁnity could prevent the formation of larger protein aggregates by
capping possible local oligomerization regions. At the same time, by
changing/altering the nature of exposed chemical groups on the protein
surface could create a potentially disturbing factor for the building up of
speciﬁc networks for polar interactions. Also at higher concentrations,
thedynamic of less deﬁned andweaker “traveling”protein-ligand inter-
actions observed for several MD models could provide aspeciﬁc extra
stabilization of helical regions and/or destabilization of further protein
aggregation.
This effect is more evident by the addition of Cef, suggesting a
stronger protective effect of this molecule, in neurological disorders
characterized by an increased production and polymerization of
GFAP.
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